DARRIN UECKER - 12 Jul 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)

Role
Chief Technology Officer, Director
Signature
/s/ Kenneth B. Stratton, as Attorney-in-Fact
Issuer symbol
PLSE
Transactions as of
12 Jul 2023
Transactions value $
$0
Form type
4
Filing time
14 Jul 2023, 20:27:44 UTC
Previous filing
06 Jul 2023
Next filing
03 Nov 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLSE Stock Option (right to buy) Award +200,000 200,000 12 Jul 2023 Common Stock 200,000 $7.08 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on July 12, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to two tranches of performance-based vesting criteria tied to Issuer's market capitalization, with no vesting until the Issuer's market capitalization exceeds $4 billion, in both cases, subject to the Reporting Person's continued service through each vesting milestone.
F2 Not applicable.